🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 70 of 116

  1. Saruparib

    AstraZeneca AB

    Advanced/Recurrent Ovarian cancer

    phase 2 small molecule active

    1 trial

  2. Saruparib, Camizestrant, Datopotamab deruxtecan, PACLITAXEL , Saruparib, DS-8201a, Saruparib, Saruparib

    AstraZeneca AB

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  3. Saruparib, ZYTIGA 500 mg film-coated tablets, Erleada 60 mg film-coated tablets, Saruparib, Xtandi - 40 mg soft capsules, Prednisone Mylan Pharma 5 mg compresse, NUBEQA 300 mg film-coated tablets, Saruparib

    AstraZeneca AB

    Metastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  4. Sasanlimab Prefilled syringe

    Pfizer

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule terminated

    1 trial

  5. Sativex

    Jazz Pharmaceuticals Ireland Limited

    Cancer

    phase 2 small molecule completed

    2 trials

  6. Savolitinib

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. Savolitinib, TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Savolitinib

    AstraZeneca AB

    EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer.

    phase 2 small molecule active

    1 trial

  8. Savolitinib, TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Savolitinib, TAGRISSO 40 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets

    AstraZeneca AB

    EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. Scemblix 20 mg film-coated tablets, Tasigna 200 mg hard capsules, Scemblix 40 mg film-coated tablets, Tasigna 150 mg hard capsules

    Novartis Pharmaceuticals

    Chronic myeloid leukemia

    phase 2 small molecule active

    1 trial

  10. Scemblix 40 mg film-coated tablets, Scemblix 40 mg film-coated tablets, Scemblix 20 mg film-coated tablets, Scemblix 40 mg film-coated tablets, NILOTINIB, NILOTINIB, Scemblix 20 mg film-coated tablets, IMATINIB, IMATINIB

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular response

    phase 2 small molecule active

    1 trial

  11. Self-hypnotic Relaxation

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 other completed

    1 trial

  12. Selinexor

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (Relapsed/Refractory)

    phase 2 small molecule active

    1 trial

  13. Selinexor

    Karyopharm Therapeutics Inc

    Carcinoma, Neuroendocrine

    phase 2 small molecule completed

    1 trial

  14. Selinexor

    Karyopharm Therapeutics Inc

    Non-small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  15. Selinexor

    Karyopharm Therapeutics Inc

    Ovarian Carcinoma

    phase 2 small molecule completed

    1 trial

  16. Selinexor

    Karyopharm Therapeutics Inc

    Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  17. Selinexor

    Karyopharm Therapeutics Inc

    Peripheral T-cell Lymphoma (PTCL)

    phase 2 small molecule terminated

    1 trial

  18. Selinexor

    Karyopharm Therapeutics Inc

    Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  19. Selinexor

    Karyopharm Therapeutics Inc

    Recurrent Small Cell Lung Carcinoma

    phase 2 small molecule terminated

    1 trial

  20. Selinexor

    Hospital Authority, Hong Kong

    Acute Myeloid Leukemia, Adult

    phase 2 small molecule terminated

    1 trial

  21. Selinexor

    Karyopharm Therapeutics Inc

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  22. Selinexor

    Karyopharm Therapeutics Inc

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule completed

    3 trials

  23. Selinexor

    Karyopharm Therapeutics Inc

    Acute Myeloid Leukemia (Relapsed/Refractory)

    phase 2 small molecule completed

    1 trial

  24. Selinexor

    Karyopharm Therapeutics Inc

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  25. Selinexor

    Karyopharm Therapeutics Inc

    Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    phase 2 small molecule terminated

    1 trial

  26. Selinexor

    Karyopharm Therapeutics Inc

    Solid Tumor Malignancy

    phase 2 small molecule terminated

    1 trial

  27. Selinexor

    Karyopharm Therapeutics Inc

    Leukemia

    phase 2 small molecule completed

    2 trials

  28. Selinexor

    Karyopharm Therapeutics Inc

    Locally Advanced Unresectable or Metastatic Melanoma

    phase 2 small molecule terminated

    1 trial

  29. Selinexor

    Karyopharm Therapeutics Inc

    Metastatic Colorectal Cancer

    phase 2 small molecule terminated

    1 trial

  30. Selinexor (KPT-330)

    Karyopharm Therapeutics Inc

    Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial

  31. Selinexor 100 mg

    Karyopharm Therapeutics Inc

    Non-Small Cell Lung Carcinoma (NSCLC)

    phase 2 small molecule completed

    1 trial

  32. Selpercatinib

    Eli Lilly and Company

    Medullary Thyroid Cancer

    phase 2 small molecule active

    1 trial

  33. Selpercatinib Monotherapy

    United Therapeutics Europe Ltd

    Differentiated Thyroid Cancer

    phase 2 small molecule active

    1 trial

  34. Selumetinib

    United Therapeutics Europe Ltd

    Metastatic Thyroid Gland Carcinoma

    phase 2 small molecule completed

    1 trial

  35. Selumetinib

    United Therapeutics Europe Ltd

    Malignant Peripheral Nerve Sheath Tumors

    phase 2 small molecule completed

    1 trial

  36. Serplulimab

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  37. Serplulimab

    The First People's Hospital of Lianyungang

    Colorectal Cancer (Diagnosis)

    phase 2 small molecule active

    1 trial

  38. Serplulimab

    The First People's Hospital of Lianyungang

    HER2-positive Gastric Cancer

    phase 2 small molecule active

    1 trial

  39. Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients (POP-Durva)

    The George Institute

    Untreated small triple negative breast cancer

    phase 2 other active

    1 trial

  40. Sigvotatug vedotin, PF-08634404

    Pfizer Australia Pty Ltd

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  41. Sindillimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  42. Sintilimab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  43. Sintilimab

    The First People's Hospital of Lianyungang

    Small Cell Lung Cancer Limited Stage

    phase 2 small molecule active

    1 trial

  44. Sintilimab

    The First People's Hospital of Lianyungang

    Multiple Primary Lung Cancer

    phase 2 small molecule active

    1 trial

  45. Sintilimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma (NPC)

    phase 2 small molecule active

    1 trial

  46. Sintilimab

    The First People's Hospital of Lianyungang

    Ovarian Clear Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  47. Sintilimab

    The First People's Hospital of Lianyungang

    Carcinoma

    phase 2 mab active

    1 trial

  48. Sintilimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Renal Cell Carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.